1. Home
  2. TNXP vs EVGN Comparison

TNXP vs EVGN Comparison

Compare TNXP & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • EVGN
  • Stock Information
  • Founded
  • TNXP 2007
  • EVGN 1999
  • Country
  • TNXP United States
  • EVGN Israel
  • Employees
  • TNXP N/A
  • EVGN N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • EVGN Agricultural Chemicals
  • Sector
  • TNXP Health Care
  • EVGN Industrials
  • Exchange
  • TNXP Nasdaq
  • EVGN Nasdaq
  • Market Cap
  • TNXP 15.1M
  • EVGN 15.8M
  • IPO Year
  • TNXP N/A
  • EVGN N/A
  • Fundamental
  • Price
  • TNXP $0.15
  • EVGN $2.61
  • Analyst Decision
  • TNXP Strong Buy
  • EVGN Strong Buy
  • Analyst Count
  • TNXP 2
  • EVGN 1
  • Target Price
  • TNXP $53.50
  • EVGN $12.00
  • AVG Volume (30 Days)
  • TNXP 25.4M
  • EVGN 27.6K
  • Earning Date
  • TNXP 11-07-2024
  • EVGN 11-13-2024
  • Dividend Yield
  • TNXP N/A
  • EVGN N/A
  • EPS Growth
  • TNXP N/A
  • EVGN N/A
  • EPS
  • TNXP N/A
  • EVGN N/A
  • Revenue
  • TNXP $12,458,000.00
  • EVGN $9,449,000.00
  • Revenue This Year
  • TNXP $62.53
  • EVGN $173.12
  • Revenue Next Year
  • TNXP $26.17
  • EVGN $33.10
  • P/E Ratio
  • TNXP N/A
  • EVGN N/A
  • Revenue Growth
  • TNXP N/A
  • EVGN 290.29
  • 52 Week Low
  • TNXP $0.12
  • EVGN $2.29
  • 52 Week High
  • TNXP $22.08
  • EVGN $10.40
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 35.86
  • EVGN 38.75
  • Support Level
  • TNXP $0.13
  • EVGN $2.48
  • Resistance Level
  • TNXP $0.18
  • EVGN $2.87
  • Average True Range (ATR)
  • TNXP 0.02
  • EVGN 0.28
  • MACD
  • TNXP 0.01
  • EVGN 0.03
  • Stochastic Oscillator
  • TNXP 30.67
  • EVGN 31.07

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

Share on Social Networks: